C3 Jian Announces Corporate Name Change and Expansion of Management Team

LOS ANGELES, California — November 29, 2016 — C3 Jian, Inc., a private clinical stage biotechnology company focused on the development and commercialization of novel therapeutics aimed at reengineering the human microbiome, announced that the Company has changed its name to C3J Therapeutics, Inc. (“C3J Therapeutics”) effective immediately.

The Company also announced that David Goesling has joined the Company as Vice President, Finance & Accounting.

“We are excited to move forward as C3J Therapeutics, a name that better reflects our focus on developing truly novel therapeutics to reengineer the human microbiome,” commented Todd Patrick, President and CEO. “Furthermore, the addition of David Goesling to our organization significantly expands the relevant industry expertise of our management team. I look forward to leveraging his deep financial and industry expertise as we advance our lead candidate C16G2 through the clinic and explore commercial opportunities in the prevention of dental caries.”

Mr. Goesling has over 30 years of financial and accounting experience with rapidly-growing companies focused on disruptive technologies. Most recently, he was an independent consultant for emerging growth companies in the biotech and technology industries. Prior to that, Mr. Goesling was the CFO of RF Surgical Systems, a venture capital backed medical device company. Prior to joining RF Surgical, he held finance and accounting positions with increasing levels of responsibility in the telecom industry. He began his career in the auditing group at Deloitte & Touche. A Certified Public Accountant, Mr. Goesling holds a BA from the University of Washington and an MBA from the University of Chicago.

About C3J Therapeutics, Inc.
C3J Therapeutics is a clinical stage biotechnology company focused on improving human health through the development and commercialization of targeted, pathogen-specific antimicrobials (STAMPs) that treat and prevent human diseases caused by microbial dysbiosis. A Phase 2 trial of lead candidate C16G2 in the prevention of dental caries is currently underway. The proprietary STAMP platform technology has potential applications to a variety of bacterial infections, and disorders, particularly related to the human microbiome. C3J is based in Los Angeles, California. For more information, please visit http://www.c3jtherapeutics.com.



Todd Patrick
President & CEO
C3J Therapeutics, Inc.
Phone: 310.665.2928 x242
Email: tpatrick@c3jtherapeutics.com


Investor Relations
Stephanie Carrington
ICR, Inc.
Phone: 646-277-1282
Email: Stephanie.Carrington@icrinc.com


James Heins
ICR, Inc.
Phone: 203-682-8251
Email: James.Heins@icrinc.com

Leave a Reply